Novartis to not go ahead with UK trial of cholesterol therapy Leqvio - report

Mar. 22, 2023 5:43 AM ETNovartis AG (NVS)By: Ravikash, SA News Editor2 Comments

Novartis (NYSE:NVS) has chosen not to go ahead with a U.K.-based main prevention trial called ORION-17, of its anti-cholesterol therapy Leqvio, which was planned as part of its collaboration with U.K.'s National Health Service (NHS) to evaluate the medicine, Reuters reported.
The Swiss pharma giant took the decision following an evaluation, the report added.
In 2021, Novartis had agreed a deal with NHS for use of Leqvio, after U.K.'s drug pricing watchdog National Institute for Health and Care Excellence (NICE) approved the drug.
Novartis had previously said that the agreement would support access to the therapy through the NHS for patients at risk of heart disease and for those conventional therapy had not worked, the report added.
The NHS noted that the agreement with Novartis remains in place, according to the report.